Arthropod-Borne Viral Infections Market By Product (Preventive Vaccines, Molecular Diagnostic Tests, Rapid Antigen Tests, Serological Tests, Laboratory Instruments and Consumables, Supportive Care Products); By Application (Dengue, Chikungunya, Zika Virus Infection, West Nile Virus Infection, Yellow Fever, Japanese Encephalitis, Tick-Borne Encephalitis, Oropouche Virus Infection, Other Emerging Arboviral Infections); By End User (Hospitals and Clinics, Diagnostic Laboratories, Public Health and Reference Laboratories, Government Immunisation Programmes, Travel Medicine Clinics, Research Institutes and Academic Laboratories); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Arthropod-Borne Viral Infections Market: Prevention, Diagnostics and Outbreak-Response Economics

The Global Arthropod-Borne Viral Infections Market was valued at USD 2.12 billion in 2025 and is projected to reach USD 3.36 billion by 2032, expanding at a CAGR of 6.8% during 2026–2032, according to Strategic Market Research.

 

Prevention remains central, with vaccines such as Dengvaxia, Qdenga, Ixchiq, and Vimkunya designed to generate durable neutralising antibody responses.The antiviral pipeline includes investigational and repurposed candidates such as mosnodenvir, celgosivir, sofosbuvir, galidesivir, and selected protease inhibitors.These therapies act by blocking viral protein interactions, RNA polymerase activity, glycoprotein folding, or other host-dependent replication processes.Alongside vaccines and drug development, mosquito-targeted vector control remains essential for interrupting transmission and reducing the overall burden of arboviral disease.

 

Dengue Defines the Largest Measurable Revenue Opportunity

Dengue accounts for the largest publicly measurable disease burden within the market. WHO recorded approximately 14.43 million reported dengue cases in 2024, including 7.72 million laboratory-confirmed cases, 52,738 severe cases and 11,201 deaths. The Americas represented more than 90% of reported global cases, while Brazil alone registered more than 10 million cases and 6,321 deaths.

The scale of reported disease directly affects diagnostic testing, hospital preparedness and public vaccination decisions. Dengue-virus testing accounted for an estimated 36% of arbovirus-testing revenue in 2025. Applied to SMR’s diagnostic-segment estimate, this represents approximately USD 0.42 billion in dengue-related testing revenue. The 7.72 million laboratory-confirmed cases also indicate substantial demand for molecular, antigen and serology testing, although the number of assays performed is higher because patients may receive more than one type of test during diagnosis and follow-up.

WHO estimates that approximately half of the global population is exposed to dengue risk and that annual infections may range from 100 million to 400 million. Commercial access remains narrower because vaccine eligibility, public funding, supply and national recommendations determine how much epidemiological need converts into revenue.

Brazil provides the clearest example of disease burden creating funded commercial demand. The country obtained approximately 6.5 million Qdenga doses for its public health programme in 2024, initially prioritising children aged 10–14. The procurement established a sizeable public vaccine market, but available supply covered only a small share of the population exposed to dengue.

Puerto Rico also illustrates the relationship between disease surveillance and healthcare utilisation. During 2024, the territory reported 6,291 dengue cases, including 3,289 hospitalisations, 264 severe cases and 11 deaths. Around 52.3% of reported cases were hospitalised, while severe disease represented 4.2% and deaths 0.2%, generating demand for diagnostic testing, emergency care, fluid management and inpatient monitoring.

 

Preventive Vaccines Reshape the Disease-Specific Value Pool

Preventive vaccines represented approximately USD 0.66 billion in 2025 and are projected to be the fastest-expanding major pathway, reaching about USD 1.28 billion by 2032 at a CAGR of 10.0%. Demand can be measured through doses, target age groups, travel requirements, routine immunisation schedules and outbreak campaigns. Commercial success depends on regulatory approval, national recommendations, public procurement, vaccine supply, safety perception and the ability of healthcare systems to complete required dosing schedules.

Takeda’s Qdenga is the most active recent dengue vaccine in international markets. WHO prequalified the vaccine in May 2024 and recommended its use among children aged 6–16 in areas with high dengue transmission. WHO prequalification supports procurement by international agencies and national programmes, while the targeted recommendation connects demand to disease burden and defined age cohorts.

India approved Qdenga in July 2026 as the country’s first authorised dengue vaccine. The approval covers people aged 4–60 and requires two doses administered three months apart. The Indian government reported that Qdenga had received approval in 42 countries and that more than 24 million doses had been distributed globally. India represents a major expansion opportunity because of its dengue burden, surveillance infrastructure and substantial private healthcare market.

Qdenga is not approved by the US FDA. Dengvaxia remains the only dengue vaccine authorised in the United States, with use limited to children aged 9–16 living in endemic areas who have laboratory-confirmed evidence of previous dengue infection. Sanofi is discontinuing the product because of insufficient global demand. Its performance demonstrates how screening requirements, limited geography and narrow eligibility can reduce adoption even when disease prevention remains a public-health priority.

Brazil is also developing domestic vaccine capacity through the Butantan Institute. Butantan-DV was approved as a single-dose dengue vaccine, with an initial public supply of approximately 1.3 million doses. A single-dose schedule could reduce programme complexity and improve completion compared with vaccines requiring multiple visits. The programme was temporarily interrupted in June 2026 during a precautionary safety reassessment, creating short-term uncertainty around rollout speed and public acceptance.

Manufacturing capacity is becoming an important competitive factor. Takeda’s partnership with Biological E is planned to add production capacity of up to 50 million Qdenga doses annually, equal to half of Takeda’s wider target of supplying 100 million doses per year by 2030. Capacity expansion can improve access to government tenders, reduce supply shortages and strengthen the commercial position of manufacturers in high-burden countries.

 

Yellow Fever Anchors High-Volume Institutional Vaccine Procurement

Yellow fever vaccination represents one of the most established and procurement-intensive segments. WHO identifies 27 high-risk countries in Africa and 13 in Latin America. Demand is created through routine childhood immunisation, preventive mass campaigns, travel requirements and emergency outbreak stockpiles.

UNICEF forecast approximately 100 million yellow fever vaccine doses for 2024 across around 40 supplied countries. Approximately 94 million doses, or 94% of forecast demand, were allocated to routine immunisation and preventive campaigns, while six million doses, or 6%, were associated with outbreak response and emergency requirements. UNICEF’s underlying procurement structure indicates that preventive campaigns represent about 70% of ordinary procured volumes, routine immunisation around 30%, and the emergency stockpile remains fixed at approximately six million doses.

Yellow fever procurement is highly price-sensitive and largely controlled through government and pooled purchasing channels. UNICEF’s January 2026 awarded-price schedule included selected multidose vaccine offers at approximately USD 1.53–USD 1.96 per dose for eligible markets, depending on supplier and presentation. Applied to the 100 million-dose forecast, this price range indicates an annual institutional procurement value of roughly USD 153 million–USD 196 million. These prices favour manufacturers with WHO-prequalified products, large-scale production, efficient distribution and a record of dependable deliveries.

 

Chikungunya Opens a High-Potential but Risk-Sensitive Vaccine Frontier

More than 620,000 chikungunya cases and 213 deaths were reported globally in 2024. The disease supports a developing vaccine opportunity, although access remains concentrated in travel medicine, occupational risk groups and populations covered by outbreak-related recommendations.

The FDA approved Bavarian Nordic’s VIMKUNYA in February 2025 for people aged 12 and older who face increased risk of exposure. The approval created a new commercial option for travellers, military personnel, laboratory workers and populations affected by local transmission. The product remains part of the higher-growth preventive-vaccine pathway, which SMR expects to expand at a 10.0% CAGR through 2032.

Valneva’s IXCHIQ illustrates the regulatory risk associated with newly launched vaccine categories. The FDA suspended the vaccine’s biologics licence in 2025 following serious post-market safety concerns. The action removed US commercial access and increased scrutiny of safety evidence, age-specific recommendations and pharmacovigilance across the chikungunya vaccine segment.

 

Laboratory Diagnostics Remain the Market’s Recurring Revenue Engine

Laboratory diagnostics led the market with an estimated 55.0% share and USD 1.17 billion in 2025 revenue. The segment is projected to reach approximately USD 1.66 billion by 2032 at a CAGR of 5.2%. Testing serves nearly every infection included in the market, including viruses without approved vaccines or treatments. Demand comes from suspected cases, outbreak surveillance, neurological illness, travel-related infection, blood-safety programmes and the need to distinguish between infections with similar clinical presentations.

RT-PCR-based tests accounted for an estimated 49.2% of diagnostic-testing revenue in 2025, equivalent to approximately USD 0.58 billion within the SMR market framework. Hospitals represented around 58.4% of diagnostic end-user revenue, or approximately USD 0.68 billion, reflecting their role in acute assessment, confirmatory testing and management of severe cases.

Dengue provides the strongest evidence of testing volume, with approximately 7.72 million laboratory-confirmed cases globally in 2024. Diagnostic demand includes molecular testing, NS1 antigen assays and IgM or other serology tests, with test selection influenced by the timing of illness and available laboratory infrastructure.

In Puerto Rico, 2024 surveillance included 4,942 RT-PCR-positive cases, representing approximately 78.6% of the 6,291 confirmed cases. NS1-only results accounted for 293 cases, or 4.7%, while 1,056 IgM-only cases represented 16.8%. The testing mix demonstrates the commercial need for broad assay portfolios rather than reliance on a single diagnostic category.

India had 869 dengue and chikungunya sentinel surveillance hospitals in 2025. These facilities form an identifiable public-sector customer base for test kits, reagents, laboratory systems, reporting platforms and quality-control services. Private hospitals and commercial laboratories increase the country’s total diagnostic opportunity beyond the government surveillance network.

Oropouche is creating a newer diagnostic and surveillance opportunity. WHO recorded 11,634 confirmed cases in the Americas through November 2024. The disease can be confused with dengue and other febrile illnesses, supporting demand for differential testing, laboratory validation and expanded regional surveillance.

 

Outbreak Severity Converts Disease Burden Into Hospital Demand

Supportive care, surveillance and outbreak-response activities accounted for an estimated 14.0% market share and nearly USD 0.30 billion in 2025 revenue. The pathway is projected to reach approximately USD 0.42 billion by 2032 at a CAGR of 5.0%. Most arthropod-borne viral infections are managed through emergency assessment, laboratory monitoring, fluid management, inpatient care and neurological support rather than disease-specific medicines.

The United States recorded 2,770 domestically acquired arboviral disease cases in 2023, including 2,022 hospitalisations and 208 deaths. West Nile virus accounted for 2,628 cases, representing approximately 95% of the reported domestic total. US clinical demand is therefore mainly associated with West Nile surveillance and acute care, while dengue demand is concentrated in travellers, imported infections and US territories.

Hospital revenue is episodic and closely linked to outbreak intensity and disease severity. Large outbreaks can place significant pressure on emergency and inpatient capacity, but utilisation may decline sharply when transmission falls. Suppliers serving hospitals benefit from infectious-disease and critical-care portfolios that extend beyond one arbovirus.

No broad virus-specific antiviral market currently exists. Investigational compounds such as mosnodenvir and repurposed candidates including celgosivir, sofosbuvir and selected protease or nucleoside inhibitors remain research assets rather than established revenue sources. Johnson & Johnson discontinued its Phase II dengue field study of mosnodenvir in 2024 as part of portfolio prioritisation, despite evidence of antiviral activity in a controlled human infection study. Future therapeutic value depends on new development partners, larger trials and regulatory progress.

 

Regional Disease Hotspots Reshape Procurement and Investment Priorities

The Americas represent the leading dengue-related demand centre, accounting for more than 90% of global reported dengue cases in 2024. Brazil combines exceptional case volumes, public Qdenga procurement and domestic vaccine development through Butantan. Puerto Rico contributes substantial diagnostic and hospital demand, while Oropouche circulation is expanding the need for differential testing in South America and the Caribbean.

Asia-Pacific combines a large dengue burden with established Japanese encephalitis vaccination programmes. WHO identifies 24 countries with Japanese encephalitis transmission risk and more than three billion people living in exposed areas. India reported 232,425 dengue cases in 2024 and has created a new commercial pathway through Qdenga approval.

Europe maintains established demand for tick-borne encephalitis vaccination. ECDC recorded 3,650 cases across 20 EU/EEA countries in 2022, including 3,516 confirmed cases, representing a 96.3% confirmation rate. Demand is concentrated among residents of endemic areas, outdoor workers and travellers. Expansion of Aedes albopictus across 16 European countries and 369 regions, alongside 27 recorded chikungunya outbreaks in 2025, is increasing investment in surveillance, preparedness and travel vaccination.

 

Competitive Advantage Shifts Toward Scale, Access and Safety Management

Takeda holds a prominent position in dengue vaccination through WHO prequalification, public procurement in Brazil, Indian approval and manufacturing expansion with Biological E. Takeda reported JPY 31.7 billion in vaccine revenue during the first half of FY2025. Reported vaccine revenue declined 16.8% on a constant-exchange-rate basis because of lower COVID-19 vaccine supply in Japan, while the company described global Qdenga demand as strong. Butantan is building a domestic single-dose alternative, while Sanofi’s Dengvaxia withdrawal reflects the commercial limits of restrictive eligibility.

Bavarian Nordic has strengthened its chikungunya position with VIMKUNYA, while Valneva’s IXCHIQ suspension demonstrates the effect of post-market safety findings on market access. Yellow fever remains a multi-supplier tender market in which WHO prequalification, production efficiency and supply reliability determine competitiveness.

By pathway, preventive vaccines represent the principal disease-specific revenue segment and the fastest-growing major category at a projected 10.0% CAGR. Diagnostics retain the largest 2025 share at 55.0%, supported by recurring testing across nearly every included infection. Supportive care contributes outbreak-sensitive hospital revenue, while antiviral therapies remain a longer-term development opportunity.

By infection, dengue forms the largest measurable demand pool, yellow fever represents the leading high-volume institutional vaccine category, chikungunya is an emerging vaccine segment, and West Nile virus supports surveillance and hospital demand in the United States. Japanese encephalitis and tick-borne encephalitis maintain established regional vaccine markets, while Oropouche is expanding diagnostic and research activity.

 

Strategic Outlook

Growth through 2032 will be shaped by dengue vaccine expansion, additional manufacturing capacity, wider laboratory surveillance, geographic spread of mosquito vectors and increasing government investment in outbreak preparedness. Suppliers capable of aligning regulatory approval, national recommendations, reliable production, public procurement and post-market safety management will secure the strongest commercial positions.

 

Arthropod-Borne Viral Infections Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 2.12 Billion
Revenue Forecast in 2032	USD 3.36 Billion
Overall Growth Rate	CAGR of 6.8% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
Segmentation	By Product, By Application, By End User, By Geography
By Product	Preventive Vaccines, Molecular Diagnostic Tests, Rapid Antigen Tests, Serological Tests, Laboratory Instruments and Consumables, Supportive Care Products
By Application	Dengue, Chikungunya, Zika Virus Infection, West Nile Virus Infection, Yellow Fever, Japanese Encephalitis, Tick-Borne Encephalitis, Oropouche Virus Infection, Other Emerging Arboviral Infections
By End User	Hospitals and Clinics, Diagnostic Laboratories, Public Health and Reference Laboratories, Government Immunisation Programmes, Travel Medicine Clinics, Research Institutes and Academic Laboratories
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, China, Japan, South Korea, India, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	Rising prevalence of mosquito and vector-borne viral infections, expanding vaccination and surveillance programmes, increasing adoption of molecular diagnostics and rapid testing technologies, growing government investment in infectious disease preparedness
Customization Option	Available upon request